Drug · CHEMBL30
CIMETIDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CIMETIDINE. Drugs and targets, record CHEMBL30. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL30
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Acid-eze, Acitak 200, Acitak 400, Acitak 800, Brumetadina, Dyspamet, Galenamet, Kentamet, Peptimax 200, Peptimax 400, Peptimax 800, Tagadine, Tagamet, Tagamet 100, Tagamet hb, Tagamet hb 200, Ultec, Valmagen, Zita
- ChEMBL
- Other names
- Aciloc, Acinil, Brumetidina, Cimal, Cimetidina, Cimetidinum, Gastromet, NSC-335308, SKF-92334, Stomedine, Ulcedin, Ulcimet, Ulcomedina
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HRH2 | Histamine H2 receptor | Histamine H2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3274 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials24
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02157376 | Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients | Phase 3 | 343 | 2017-01-23 | cimetidine | Its name | ClinicalTrials.gov |
| NCT01757275 | High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer | Phase 3 | 239 | 2016-03-08 | cimetidine | Its name | ClinicalTrials.gov |
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | Phase 2/3 | 130 | 2025-08-20 | cimetidine | Its name | ClinicalTrials.gov |
| NCT04493931 | Drug-drug Interaction Study of Gepotidacin | Phase 1 | 64 | 2022-03-04 | cimetidine | Its name | ClinicalTrials.gov |
| NCT03307252 | This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men | Phase 1 | 45 | 2019-07-12 | cimetidine | Its name | ClinicalTrials.gov |
| NCT00515073 | Papillary Serous Carcinoma of the Endometrium | Phase 2 | 30 | 2014-07-03 | cimetidine | Its name | ClinicalTrials.gov |
| NCT01256879 | Cimetidine Biowaivers | Phase 4 | 25 | 2019-08-28 | cimetidine | Its name | ClinicalTrials.gov |
| NCT05365451 | Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters | Early phase 1 | 16 | 2025-08-08 | cimetidine | Its name | ClinicalTrials.gov |
| NCT02703896 | Prophylaxis for Aspiration of Gastric Contents. | Phase 4 | 1,920 | cimetidine | Its name | ClinicalTrials.gov | |
| NCT00045799 | Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill | Phase 3 | 354 | cimetidine | Its name | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cimetidine vs Esomeprazole: serious adverse events | 12 of 153 | 14 of 147 | 300 | NCT02157376 | Trial comparisons |
| Esomeprazole vs Cimetidine: serious adverse events | 5 of 110 | 5 of 105 | 215 | NCT01757275 | Trial comparisons |
Arm I (Paclitaxel, Pre-medications) vs Arm II (Paclitaxel): Proportion of Patients With Grade 2 or Greater Reactions That Require Parenteral Rescue Medications to Treat an Infusion Hypersensitivity Reaction (HSR) After the First 2 Doses of Paclitaxel With or Without Continued Premedication Dosing | 0 of 46 | 1 of 43 | 89 | NCT04862585 | Trial comparisons |
Papers from its trials8
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL30
GET https://conductscience.org/api/drugs/v1/CHEMBL30/trials?page=2